Literature DB >> 15233204

Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog.

L J Hofland1.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 15233204

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  5 in total

1.  Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia.

Authors:  David L Kleinberg; Pietro Ameri; Baljit Singh
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

2.  Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.

Authors:  Saman Sizdahkhani; Michael J Feldman; Martin G Piazza; Alexander Ksendzovsky; Nancy A Edwards; Abhik Ray-Chaudhury; Dragan Maric; Marsha J Merrill; Karel Pacak; Zhengping Zhuang; Prashant Chittiboina
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

Review 3.  Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.

Authors:  Mahjabin Khan; Tao Huang; Cheng-Yuan Lin; Jiang Wu; Bao-Min Fan; Zhao-Xiang Bian
Journal:  Oncotarget       Date:  2017-06-07

4.  Ectopic Cushing's syndrome due to adrenocorticotropic hormone secreting atypical thymic carcinoid tumor.

Authors:  Cevdet Duran; Meryem Ilkay Eren Karanis; Suleyman Bakdik; Uysaler Aslan; Mustafa Calik; Saniye Goknil Calik
Journal:  North Clin Istanb       Date:  2018-08-07

5.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.